Einloggen

Thematische Bibliographien / Late-onset Pome disease / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Late-onset Pome disease.

Zeitschriftenartikel zum Thema „Late-onset Pome disease“

Autor: Grafiati

Veröffentlicht am 30. Juni 2021

Zuletzt aktualisiert am 29. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Late-onset Pome disease" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Safina, D. R., L. R. Alimbekova, and A. T. Faskhutdinov. "Late-onset Pompe disease." Clinical pharmacology and therapy 35, no. 3 (2024): 63–66. http://dx.doi.org/10.32756/0869-5490-2024-3-63-66.

Der volle Inhalt der Quelle

Annotation:

Pompe disease is a rare neuromuscular disorder associated with acid maltase deficiency. The severity of clinical manifestations and age of onset correlate with the type of mutation in the GAA gene and residual activity of lysosomal α-1,4-glucosidase. The infantile form of Pompe disease is characterized by hypertrophic cardiomyopathy, generalized muscle weakness, hypotonia, hepatomegaly and death from respiratory failure within the first year of life. Late-onset Pompe disease may develop at any age and affects skeletal muscle, causing slowly progressive muscle weakness and respiratory impairmen

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Mattosova, S., A. Hlavata, P. Spalek, L. Kotysova, D. Macekova, and J. Chandoga. "Late onset form of Pompe disease." Bratislava Medical Journal 116, no. 08 (2015): 502–5. http://dx.doi.org/10.4149/bll_2015_097.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Schneider, Joseph, Lynn A. Burmeister, Kyle Rudser, Chester B. Whitley, and Jeanine Jarnes Utz. "Hypothyroidism in late-onset Pompe disease." Molecular Genetics and Metabolism Reports 8 (September 2016): 24–27. http://dx.doi.org/10.1016/j.ymgmr.2016.06.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Roberts, Mark. "Late-Onset Pompe Disease: A Multisystemic Disorder." Journal of Neuromuscular Diseases 2, s1 (2015): S1. http://dx.doi.org/10.3233/jnd-159001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Mišurová, Radka, and Věra Malinová. "The late-onset form of Pompe disease." Neurologie pro praxi 22, no. 4 (2021): 325–30. http://dx.doi.org/10.36290/neu.2021.053.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Goker-Alpan, Ozlem, Vellore G. Kasturi, Maninder K. Sohi, et al. "Pregnancy Outcomes in Late Onset Pompe Disease." Life 10, no. 9 (2020): 194. http://dx.doi.org/10.3390/life10090194.

Der volle Inhalt der Quelle

Annotation:

There is limited data on pregnancy outcomes in Pompe Disease (PD) resulting from deficiency of the lysosomal enzyme acid alpha-glucosidase. Late-onset PD is characterized by progressive proximal muscle weakness and decline of respiratory function secondary to the involvement of the respiratory muscles. In a cohort of twenty-five females, the effects of both PD on the course of pregnancy and the effects of pregnancy on PD were investigated. Reproductive history, course of pregnancy, use of Enzyme replacement therapy (ERT), PD symptoms, and outcomes of each pregnancy were obtained through a ques

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Frezza, E., C. Terracciano, M. Giacanelli, E. Rastelli, G. Greco, and R. Massa. "Late-Onset Pompe Disease with Nemaline Bodies." Case Reports in Neurological Medicine 2018 (September 27, 2018): 1–5. http://dx.doi.org/10.1155/2018/4127213.

Der volle Inhalt der Quelle

Annotation:

Pompe disease is an autosomal recessive disorder characterized by deficiency of alpha-glucosidase, a lysosomal enzyme, which can lead to glycogen accumulation in skeletal muscle, heart, and nervous system. Clinical presentation is highly variable, with infantile and late-onset (LOPED) forms. Although muscle biopsy findings are rather stereotyped, atypical features have been described. A 52-year-old man without a family history of muscle disorders presented with slowly progressing upper and lower limb girdle weakness and hyperCKemia. At needle EMG, a diffuse neurogenic pattern was detected. Mus

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Jones, Harrison, Kelly Crisp, Milisa Batten, et al. "Lingual pathophysiology in late-onset Pompe disease." Molecular Genetics and Metabolism 123, no. 2 (2018): S72. http://dx.doi.org/10.1016/j.ymgme.2017.12.178.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Xirou, S., C. Papadopoulos, V. Nikolakopoulou, et al. "ERT efficacy in late onset Pompe disease." Neuromuscular Disorders 26 (October 2016): S110. http://dx.doi.org/10.1016/j.nmd.2016.06.090.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Lamartine S.Monteiro, M., and G. Remiche. "Late-onset Pompe disease associated with polyneuropathy." Neuromuscular Disorders 29, no. 12 (2019): 968–72. http://dx.doi.org/10.1016/j.nmd.2019.08.016.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Yang, C. F., D. M. Niu, M. J. Jeng, Y. S. Lee, P. C. Taso, and W. J. Soong. "Late-Onset Pompe Disease With Left-Sided Bronchomalacia." Respiratory Care 60, no. 2 (2014): e26-e29. http://dx.doi.org/10.4187/respcare.03419.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Berresford, S. "Alglucosidase-?? of benefit in late-onset Pompe disease." Inpharma Weekly &NA;, no. 1635 (2008): 13. http://dx.doi.org/10.2165/00128413-200816350-00023.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Jastrzębska, Aleksandra, Anna Potulska‐Chromik, Anna Łusakowska, et al. "Screening for late‐onset Pompe disease in Poland." Acta Neurologica Scandinavica 140, no. 4 (2019): 239–43. http://dx.doi.org/10.1111/ane.13133.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

McIntosh, Paul, Laura Case, Stephanie Austin, and Priya Kishnani. "Characterization of gait in late onset Pompe disease." Molecular Genetics and Metabolism 114, no. 2 (2015): S78. http://dx.doi.org/10.1016/j.ymgme.2014.12.171.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

McIntosh, Paul T., Laura E. Case, Justin M. Chan, Stephanie L. Austin, and Priya Kishnani. "Characterization of gait in late onset Pompe disease." Molecular Genetics and Metabolism 116, no. 3 (2015): 152–56. http://dx.doi.org/10.1016/j.ymgme.2015.09.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Hamed, Alaa, Andrew Stewart, Milki Tilimo, Robert Krupnick, LeAnne Maddux, and Margaret Meyer. "PRO instrument development for late-onset Pompe disease." Molecular Genetics and Metabolism 120, no. 1-2 (2017): S61—S62. http://dx.doi.org/10.1016/j.ymgme.2016.11.140.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Jones, Harrison N., Kaylea Nicholson, and Kelly D. Crisp. "Respiratory muscle training in late-onset Pompe disease." Molecular Genetics and Metabolism 120, no. 1-2 (2017): S72. http://dx.doi.org/10.1016/j.ymgme.2016.11.169.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Finsterer, Josef. "Late-onset Pompe disease manifests in the brain." Molecular Genetics and Metabolism Reports 20 (September 2019): 100488. http://dx.doi.org/10.1016/j.ymgmr.2019.100488.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Palmio, Johanna, Mari Auranen, Sari Kiuru-Enari, Mervi Löfberg, Olaf Bodamer, and Bjarne Udd. "Screening for late-onset Pompe disease in Finland." Neuromuscular Disorders 24, no. 11 (2014): 982–85. http://dx.doi.org/10.1016/j.nmd.2014.06.438.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Panosyan, Francis B., Michael F. Fitzpatrick, and Charles F. Bolton. "Late Onset Pompe Disease Mimicking Rigid Spine Syndrome." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 41, no. 2 (2014): 286–89. http://dx.doi.org/10.1017/s0317167100016760.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Laforêt, Pascal, Valérie Doppler, Catherine Caillaud, et al. "Rigid spine syndrome revealing late-onset Pompe disease." Neuromuscular Disorders 20, no. 2 (2010): 128–30. http://dx.doi.org/10.1016/j.nmd.2009.11.006.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Papadimas, G. K., G. Terzis, S. Methenitis, et al. "Body composition analysis in late-onset Pompe disease." Molecular Genetics and Metabolism 102, no. 1 (2011): 41–43. http://dx.doi.org/10.1016/j.ymgme.2010.09.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Musumeci, Olimpia, and Antonio Toscano. "Diagnostic tools in late onset Pompe disease (LOPD)." Annals of Translational Medicine 7, no. 13 (2019): 286. http://dx.doi.org/10.21037/atm.2019.06.60.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Fayssoil, Abdallah, Olivier Nardi, Djillali Annane, and David Orlikowski. "Right ventricular function in late-onset Pompe disease." Journal of Clinical Monitoring and Computing 28, no. 4 (2014): 419–21. http://dx.doi.org/10.1007/s10877-014-9551-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Cupler, Edward J., Kenneth I. Berger, Robert T. Leshner, et al. "Consensus treatment recommendations for late-onset Pompe disease." Muscle & Nerve 45, no. 3 (2011): 319–33. http://dx.doi.org/10.1002/mus.22329.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Labella, Beatrice, Stefano Cotti Piccinelli, Barbara Risi, et al. "A Comprehensive Update on Late-Onset Pompe Disease." Biomolecules 13, no. 9 (2023): 1279. http://dx.doi.org/10.3390/biom13091279.

Der volle Inhalt der Quelle

Annotation:

Pompe disease (PD) is an autosomal recessive disorder caused by mutations in the GAA gene that lead to a deficiency in the acid alpha-glucosidase enzyme. Two clinical presentations are usually considered, named infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD), which differ in age of onset, organ involvement, and severity of disease. Assessment of acid alpha-glucosidase activity on a dried blood spot is the first-line screening test, which needs to be confirmed by genetic analysis in case of suspected deficiency. LOPD is a multi-system disease, thus requiring a multidisc

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Papadimas, George, Gerassimos Terzis, Constantinos Papadopoulos, et al. "Bone density in patients with late onset Pompe disease." International Journal of Endocrinology and Metabolism 10, no. 4 (2012): 599–603. http://dx.doi.org/10.5812/ijem.4967.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Musumeci, Olimpia, Carmen Terranova, Alessia Pugliese, Vincenzo Rizzo, Paolo Girlanda, and Antonio Toscano. "Electromyographic findings in patients with late-onset pompe disease." Journal of the Neurological Sciences 429 (October 2021): 119360. http://dx.doi.org/10.1016/j.jns.2021.119360.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Hansen, J. S., E. G. Pedersen, D. Gaist, et al. "Screening for late-onset Pompe disease in western Denmark." Acta Neurologica Scandinavica 137, no. 1 (2017): 85–90. http://dx.doi.org/10.1111/ane.12811.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Hernandez, Zachary, Kelly Wickstrom, and Tammer El-Aini. "Medical image of the month: late-onset Pompe disease." Southwest Journal of Pulmonary and Critical Care 20, no. 4 (2020): 124–25. http://dx.doi.org/10.13175/swjpcc022-20.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Croce, M., F. Naz, L. Barzaghi, et al. "673P Magnetization transfer imaging in late-onset Pompe disease." Neuromuscular Disorders 43 (October 2024): 104441.731. http://dx.doi.org/10.1016/j.nmd.2024.07.740.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Ruiz, Agustin Gutierrez, Joaquina Prieto Prieto, Amaia Laita Legarreta, and Maria Carmen Percaz Bados. "No. 15 Pompe Disease Late-Onset: A Case Report." PM&R 6, no. 8 (2014): S100. http://dx.doi.org/10.1016/j.pmrj.2014.08.293.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Papadopoulos, C., G. K. Papadimas, H. Michelakakis, E. Kararizou, and P. Manta. "Highlighting intrafamilial clinical heterogeneity in late-onset Pompe disease." Molecular Genetics and Metabolism Reports 1 (2014): 2–4. http://dx.doi.org/10.1016/j.ymgmr.2013.10.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Schneider, Ilka, Ole Hensel, and Stephan Zierz. "Response: Late-onset Pompe disease manifests in the brain." Molecular Genetics and Metabolism Reports 21 (December 2019): 100516. http://dx.doi.org/10.1016/j.ymgmr.2019.100516.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Kostera-Pruszczyk, A., A. Potulska-Chromik, A. Lusakowska, et al. "Screening for late onset Pompe disease – Single center experience." Neuromuscular Disorders 26 (October 2016): S107. http://dx.doi.org/10.1016/j.nmd.2016.06.081.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Monteiro, Sergio G., and Eduardo L. De Vito. "Blunted respiratory drive response in late onset Pompe disease." Neuromuscular Disorders 27, no. 2 (2017): 201–2. http://dx.doi.org/10.1016/j.nmd.2016.12.015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Kurashige, T., N. Shiroma, A. Motoda, et al. "P.17.2 Late onset Pompe disease with dilated cardiomyopathy." Neuromuscular Disorders 23, no. 9-10 (2013): 826–27. http://dx.doi.org/10.1016/j.nmd.2013.06.652.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Gupta, Punita, Edward C. Nunziato, and Swati Sathe. "Prevalence of late onset Pompe disease in unclassified LGMD." Molecular Genetics and Metabolism 108, no. 2 (2013): S45. http://dx.doi.org/10.1016/j.ymgme.2012.11.102.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Hagemans, M. L. C., S. P. M. Schie, A. C. J. W. Janssens, P. A. Doorn, A. J. J. Reuser, and A. T. Ploeg. "Fatigue: an important feature of late-onset Pompe disease." Journal of Neurology 254, no. 7 (2007): 941–45. http://dx.doi.org/10.1007/s00415-006-0434-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Dobbins, Julia, Tim Pyragius, Kristian Brion, et al. "112 Blood spot testing for late onset pompe disease." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 6 (2018): A44.2—A44. http://dx.doi.org/10.1136/jnnp-2018-anzan.111.

Der volle Inhalt der Quelle

Annotation:

IntroductionPompe disease is classified by age of onset and presentation. Late-onset Pompe disease (LOPD) generally presents with progressive limb-girdle and respiratory muscle weakness. Diagnosis is confirmed following dried blood spot (DBS) enzyme assay by a second method, either mutation or glucose tetra-saccharide analysis.MethodsFrom 2000 to 2016, acid α –glucosidase (GAA) activity in DBS was measured using the immuno-capture assay of . Umapathysivam et al. (2001) From 2016 testing used the multiplex tandem mass spectrometry method (6-PLEX LC-MSMS, Perkin Elmer), measuring six lysosomal s

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Matsui, Misa, Kimiko Inoue, Saburo Sakoda, et al. "Screening for late-onset Pompe disease in undiagnosed myopathies." Neurology and Clinical Neuroscience 5, no. 2 (2016): 60–64. http://dx.doi.org/10.1111/ncn3.12108.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Faraguna, Martha Caterina, Viola Crescitelli, Anna Fornari, et al. "Treatment Dilemma in Children with Late-Onset Pompe Disease." Genes 14, no. 2 (2023): 362. http://dx.doi.org/10.3390/genes14020362.

Der volle Inhalt der Quelle

Annotation:

In recent years, there has been a significant increase in the diagnosis of asymptomatic Late-Onset Pompe Disease (LOPD) patients, who are detected via family screening or Newborn Screening (NBS). The dilemma is when to start Enzyme Replacement Therapy (ERT) in patients without any clinical sign of the disease, considering its important benefits in terms of loss of muscle but also its very high cost, risk of side effects, and long-term immunogenicity. Muscle Magnetic Resonance Imaging (MRI) is accessible, radiation-free, and reproducible; therefore, it is an important instrument for the diagnos

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Angelini, Corrado, Marco Savarese, Marina Fanin, and Vincenzo Nigro. "Next generation sequencing detection of late onset pompe disease." Muscle & Nerve 53, no. 6 (2016): 981–83. http://dx.doi.org/10.1002/mus.25042.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Schüller, Angela, Stephan Wenninger, Nicola Strigl-Pill, and Benedikt Schoser. "Toward deconstructing the phenotype of late-onset Pompe disease." American Journal of Medical Genetics Part C: Seminars in Medical Genetics 160C, no. 1 (2012): 80–88. http://dx.doi.org/10.1002/ajmg.c.31322.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Hobson-Webb, Lisa D., and Priya S. Kishnani. "How common is misdiagnosis in late-onset pompe disease?" Muscle & Nerve 45, no. 2 (2012): 301–2. http://dx.doi.org/10.1002/mus.22296.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Leontieva, I. V., Yu S. Isaeva, I. M. Miklashevich, and S. A. Thermosesov. "Cardiovascular system damage in the late-onset Pompe disease." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 68, no. 3 (2023): 83–91. http://dx.doi.org/10.21508/1027-4065-2023-68-3-83-91.

Der volle Inhalt der Quelle

Annotation:

The article presents a clinical case of metabolic hypertrophic cardiomyopathy against the background of a late-onset form of Pompe disease, illustrating the difficulties of differential diagnostic search for the cause of the disease. The clinical, laboratory and genetic aspects of the diagnosis of Pompe disease are highlighted. The features of laboratory diagnostics, the difficult path to the correct diagnosis and the appointment of enzyme replacement therapy are discussed. Much attention is paid to the clinical symptoms of the disease — the most significant damage to the cardiovascular system

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Borelli, Elena, Maria Luisa Casciana, Claudia Salemi, Silvia Sordelli, and Silvia Fasoli. "IperCKemia asintomatica: la malattia di Pompe late-onset." Medico e Bambino pagine elettroniche 24, no. 4 (2021): 105–8. http://dx.doi.org/10.53126/mebxxiv105.

Der volle Inhalt der Quelle

Annotation:

The paper reports the case of a 7-year-old boy who presented with elevated alanine and aspartate transaminases. Further investigations demonstrated elevated creatine kinase (CK), so an underlying metabolic disorder was investigated even in absence of clinical manifestations. Dried blood spot (DBS) screening test for acid α-glucosidase (AAG) enzyme activity was below normal levels and molecular genetic testing for AAG gene demonstrated pathogenic mutations. The diagnosis of late-onset Pompe disease (LOPD) was finally confirmed. Thanks to the early diagnosis, the child would be under close surve

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Salinas-Suikouski, Robert, Fabricio González-Andrade, and Gabriela Aguinaga-Romero. "Enfermedad de Pompe de inicio tardío desencadenada por el embarazo, reporte de una variante clínica genómica descrita por primera vez en un adulto." Revista Ecuatoriana de Neurologia 29, no. 2 (2020): 113–18. http://dx.doi.org/10.46997/revecuatneurol29200113.

Der volle Inhalt der Quelle

Annotation:

Antecedentes: esta es la primera vez en el mundo que la variante NM_000152 (GAA_V001): c.1555A˃G; p. (Met519Val), se describe en una mujer adulta, desencadenada por el embarazo. Es una mutación sin sentido por sustitución, homocigótica, probablemente patógena. Reporte del caso: se trata de una mujer adulta mestiza, nacida y residente en Ecuador, que durante su período de lactancia, después de un embarazo y un parto por cesárea, debutó con un trastorno musculoesquelético. Se hospitalizó a la paciente en el Hospital Eugenio Espejo en Quito, Ecuador; donde ella ha sido readmitida por varias veces

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Smertina, L. P., F. I. Ausheva, A. V. Gryaznov, D. A. Svetlakov, and L. N. Kolbasin. "Late-onset Pompe disease: preliminary results of enzyme replacement therapy." Neuromuscular Diseases 9, no. 2 (2019): 43–49. http://dx.doi.org/10.17650/2222-8721-2019-9-2-43-49.

Der volle Inhalt der Quelle

Annotation:

Pompe disease is an orphan hereditary accumulation disease associated with a deficiency of the lysosomal enzyme alglucosidase alpha. Manifestations of the disease are associated with pathological deposition of glycogen in body tissues as a result of GAA gene mutation and subsequent reduction in the activity of the enzyme alglucosidase alpha or acid maltase. The variety of phenotypic forms and varying degrees of damage to the skeletal and respiratory muscles, cardiomyocytes and internal organs greatly complicates the diagnosis and treatment of patients with Pompe»s disease. This article describ

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Jaskuła, Karolina, Konrad Merkisz, Sylwia Nemeczek, et al. "Late-onset Pompe disease - literature review and summary of current knowledge." Quality in Sport 9, no. 1 (2023): 11–18. http://dx.doi.org/10.12775/qs.2023.09.01.001.

Der volle Inhalt der Quelle

Annotation:

Introduction: Pompe disease is a glycogen storage disorder caused by the deficient activity of the lysosomal enzyme acid α-glucosidase (GAA). Mutations in the GAA gene lead to the accumulation of glycogen in different organs. In a late-onset form (late-onset Pompe disease), the disease is characterized by slow, progressive proximal limb and respiratory muscle weakness. The diagnosis is based on a low level of GAA either in the muscle biopsy or in the leucocytes. LOPD is treated with enzyme replacement therapy (ERT). Purpose: Summary of currently knowladge about Late-onset Pompe disease - chara

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!